Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Member Organization News

Gemphire Begins Enrolling Patients for Cholesterol Drug Trial

Wednesday, December 7, 2016   (0 Comments)
Posted by: Kate Oesterle
Share |

Focus is those with high cholesterol not controlled by statins

Livonia-based Gemphire Therapeutics Inc. (Nasdaq:GEMP) announced Monday that it is enrolling patients for a Phase 2b study of patients whose high cholesterol isn't adequately controlled with high-intensity or moderate-intensity statin drugs.

The company will do randomized 12-week trials of its lead drug candidate, gemcabene, enrolling 104 patients with high levels of low density lipoprotein cholesterol, the so-called bad cholesterol known as LDL-C.

"If we are successful in obtaining approval for gemcabene in these populations, we expect to be able to reach a large market of over 10 million patients just in the U.S. that are currently unable to attain their LDL-C goals," said Mina Sooch, the company's president and CEO, in a news release.

Read full article.

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal